Puma anticipates $192M–$198M NERLYNX revenue for 2025 as company advances alisertib trials Puma anticipates $192M–$198M NERLYNX revenue for 2025 as company advances alisertib trials Post ContentpbyiRead More You might also be interested in reading Brandt Issues Red-Hot XRP Price Warning: Double Top?. August 8, 2025 In Mainstream ← Previous post Next post →